Crossmark

ALK-positive histiocytosis with central nervous system involvement successfully treated with alectinib: a rare case report

Published Online: 2024-08-05

Published Print: 2024-12

Authors

Zhao, Danqing

Sun, Jian

Cao, Xinxin https://orcid.org/0000-0001-7884-3073
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82370179)

National High Level Hospital Clinical Research Funding (2022-PUMCH-B-046)

Natural Science Foundation of Beijing Municipality (L222081)
License Information

Text and Data Mining valid from 2024-08-05

Version of Record valid from 2024-08-05
More Information

Article History

Received: 21 May 2024

Accepted: 29 July 2024

First Online: 5 August 2024

Declarations

:

: Ethical approval was waived by the local Ethics Committee of Peking Union Medical College Hospital in view of the retrospective nature of the study. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

: On behalf of all authors, the corresponding author states that there is no conflict of interest.

Document is current